Pharma Mar (NASDAQ:PHMMF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday.

According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “

Shares of Pharma Mar (PHMMF) opened at 4.4000 on Friday. Pharma Mar has a 52-week low of $2.40 and a 52-week high of $4.80. The firm has a 50-day moving average of $4.46 and a 200 day moving average of $4.01. The firm’s market cap is $1.09 billion.

COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Downgrades Pharma Mar (PHMMF) to Hold” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/09/zacks-investment-research-downgrades-pharma-mar-phmmf-to-hold.html.

Get a free copy of the Zacks research report on Pharma Mar (PHMMF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.